WO2012011269A1 - ステント用カバー部材及びステント装置 - Google Patents
ステント用カバー部材及びステント装置 Download PDFInfo
- Publication number
- WO2012011269A1 WO2012011269A1 PCT/JP2011/004080 JP2011004080W WO2012011269A1 WO 2012011269 A1 WO2012011269 A1 WO 2012011269A1 JP 2011004080 W JP2011004080 W JP 2011004080W WO 2012011269 A1 WO2012011269 A1 WO 2012011269A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stent
- cover member
- diameter
- blood vessel
- balloon
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/89—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure the wire-like elements comprising two or more adjacent rings flexibly connected by separate members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
- A61F2002/075—Stent-grafts the stent being loosely attached to the graft material, e.g. by stitching
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/003—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in adsorbability or resorbability, i.e. in adsorption or resorption time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/16—Materials with shape-memory or superelastic properties
Definitions
- the present invention relates to a stent cover member that expands a diameter when implanted in a blood vessel or the like and supports the blood vessel from the inside thereof, and a stent device using the cover member. .
- a site where a stenosis has occurred in a blood vessel of a living body, particularly a blood vessel such as a coronary artery is expanded using a medical balloon catheter, and a cylindrical stent is implanted into the expanded site and supported from the inside by the stent. Therefore, treatment by percutaneous coronary angioplasty (PTCA) employing stent placement that ensures blood flow has been performed.
- PTCA percutaneous coronary angioplasty
- the present inventors use a bioabsorbable polymer material that disappears in a living body after a certain period of time after implantation into the blood vessel of the living body for the purpose of reducing the burden on the post-operative patient.
- the stents formed in this way are proposed in WO92 / 15342 (Patent Document 1), WO00 / 13737 (Patent Document 2), and further proposed in WO2009 / 157164 (Patent Document 3).
- These stents are formed into a cylindrical shape using a bioabsorbable polymer material having shape memory characteristics, and are shape-memorized in an expanded size having an outer diameter that supports a blood vessel from the inside. Yes.
- the stent is heated by the body temperature of the living body and maintained in a state where the diameter has been expanded to a shape memory size, and supports the blood vessel from the inside.
- This type of stent is attached to a catheter, inserted into a blood vessel together with the catheter, and implanted at a lesion site in the vessel.
- the stent expanded to a size that supports the blood vessel from the inside has a size that has a sufficiently small outer diameter compared to the shape-memory size in order to enable smooth insertion into the blood vessel. It is attached to the catheter in a reduced state.
- a stent made of a bioabsorbable polymer material has a size having an outer diameter that is implanted in a blood vessel and heated by the body temperature of the living body and has a shape memory because of the nature of the bioabsorbable polymer material constituting the stent.
- the diameter is increased, the diameter is gradually increased over a certain time without sharply expanding. This is because the bioabsorbable polymer has properties as a viscoelastic body, and viscous resistance acts when the diameter of the bioabsorbable polymer is expanded to a size memorized.
- the stent requires time for diameter expansion.
- the stent formed using the bioabsorbable polymer material is transferred to the lesion site, which is the implantation position in the blood vessel, and then immediately expanded to a size that supports the inner wall of the blood vessel.
- the diameter of the balloon is expanded by using the expansion force of the balloon which can be expanded rapidly by injection of.
- the stent formed using the bioabsorbable polymer material that is expanded by utilizing the expansion force of the balloon is attached in a state of being contracted and being folded at the distal end portion of the catheter. It is mounted on a balloon and transported to the implantation site in the blood vessel together with the balloon. Then, when the blood vessel is transferred to a desired implantation position, the balloon is expanded by supplying an expansion medium, and the blood vessel is rapidly expanded to a size that supports the blood vessel from the inside and implanted into the lesion site.
- the stent made of a bioabsorbable polymer material is expanded, the expansion medium is extracted from the balloon, and even after the balloon is contracted, the stent retains its shape memory size by self-expanding force. The site where the stent is implanted is supported from the inside, and a blood flow path is secured in the blood vessel.
- a stent that is formed using a bioabsorbable polymer material and has a shape memory that has an expanded diameter that supports a blood vessel in an expanded state from the inside thereof
- a self-expanding force is applied that recovers the shape from the state of being diameter-reduced from the state of being diameter-reduced, heated by the body temperature.
- the stent that has been reduced in diameter and attached to be crimped onto the balloon is expanded in diameter and separated from the balloon. For this reason, the stent mounted on the balloon receives a frictional force caused by contact with the inner wall of the blood vessel during insertion into the blood vessel, and causes displacement or dropping of the balloon.
- the stent falls off the balloon, it cannot be expanded rapidly due to the expansion force of the balloon, and it cannot be implanted accurately in a desired site such as a lesion site. Even if the stent does not fall off from the balloon, if the position of the stent is displaced, the stent cannot receive the expansion force of the balloon uniformly over the entire length. The diameter is not expanded over the entire length. Thus, if the diameter of the stent is not uniformly expanded over the entire length, the desired site in the blood vessel cannot be accurately supported.
- PTCA In PTCA, it has been reported that restenosis occurs with a high probability when stenting is employed. In order to suppress such restenosis, a coating agent containing a drug having an intimal growth inhibitory effect or a drug having a thrombus formation inhibitory effect is deposited on the surface, and the drug is released over a certain period of time.
- a drug release type stent has been proposed in Japanese Patent Application Laid-Open No. 2008-253707 (Patent Document 4). However, if the stent falls off the balloon or is displaced, and cannot be accurately implanted at a desired indwelling position in the blood vessel, the drug carried on the stent may be released to the desired drug administration site. It becomes impossible.
- Patent Document 5 a stent supply device in which a balloon catheter having a stent mounted on the outer peripheral side was inserted into a protective sheath. Yes.
- this stent supply device when the stent is protruded from the protective sheath and expanded in diameter, the one end side of the stent is held by the holding member in order to prevent displacement with respect to the balloon.
- the stent supply device as described above can maintain the state where the stent is mounted on the balloon by preventing expansion of the reduced diameter stent, the provision of the protective sheath makes the structure complicated and difficult to manufacture.
- a stent supply device using a protective sheath after inserting a balloon with a stent attached to the vicinity of the implantation position, the protective sheath is advanced and retracted with respect to the catheter in order to project the balloon from the distal end of the protective sheath. It is necessary to operate, and the stent implantation operation becomes complicated.
- an object of the present invention is formed by a bioabsorbable polymer material without using a protective sheath and the like, and is memorized in a size that expands beyond the inner diameter of the vessel when implanted in the vessel.
- a stent cover member that can be reliably mounted and supported on the balloon of a balloon catheter in a state in which the diameter of the stent, which has been heated by the body temperature and expanded in diameter, is reduced, and the stent cover member is used. It is to provide a stent device.
- Another object of the present invention is to provide a stent cover member that is implanted in a blood vessel together with a stent formed of a bioabsorbable polymer material and can be lost in the living body, and does not require removal from the living body. It is providing the stent apparatus using the cover member for stents.
- Still another object of the present invention is to provide a stent cover member that can support the stent without obstructing the expansion of the stent that is expanded by expansion of the balloon, and a stent device using the stent cover member. There is to do.
- Still another object of the present invention is to provide a stent cover member that can be implanted into a living body together with a stent, thereby releasing a drug to a lesion site where the stent is implanted, and suppressing intimal proliferation, Furthermore, it is providing the stent apparatus which can suppress formation of a thrombus.
- the present invention proposed for achieving the above-mentioned object is formed in a cylindrical shape by a bioabsorbable polymer material having shape memory characteristics, and when the vessel is implanted in the vessel, A stent cover member that covers a stent whose shape is stored in a size that can be supported from the outer periphery from the outer peripheral side, and that supports the stent in a state in which the diameter is reduced from the size that is stored in the shape.
- the member is formed in a cylindrical shape from a bioabsorbable polymer material having elasticity, and has a size having an inner peripheral diameter that supports a stent to be mounted in a reduced diameter state on the balloon of the balloon catheter. And at least when the diameter of the stent is expanded to a shape memory size, it is plastically deformed to release the support of the stent.
- the bioabsorbable polymer material constituting the stent cover member is a copolymer (LCL) of poly L-lactide (PLLA) and poly ⁇ -caprolactone (PCL), and the composition ratio of the PLLA and the PCL is The molar ratio (mol%) is desirably in the range of 95 to 20: 5 to 80.
- the stent cover member contains at least one of a drug having an intimal growth inhibitory effect and a drug having a thrombus formation inhibitory effect.
- the epigallocatechin garade (EGCg) which makes purity 94% or more is used, and this EGCg is the bioabsorbable polymer material 100 which comprises the cover member for stents. 1 to 30 parts by weight are added to parts by weight.
- the present invention relates to a stent that is formed into a tubular shape from a bioabsorbable polymer material having shape memory characteristics, and has a shape memory that is sized to support the vessel from the inside when implanted in the vessel.
- the stent cover member covers the stent that is reduced in diameter and is mounted on the balloon of the balloon catheter from the outer peripheral side, and supports the stent in a state in which the diameter is reduced from the size memorized.
- the stent cover member is formed in a cylindrical shape from a bioabsorbable polymer material having elasticity, and has a size having an inner peripheral diameter that supports the stent in a reduced diameter state, and at least a size in which the stent is shape-memoryd. When the diameter of the stent is expanded, it deforms plastically to release the support of the stent.
- the stent cover member preferably has an elastic modulus at 37 ° C. in the range of 2 ⁇ 10 7 to 2 ⁇ 10 9 Pascals (Pa).
- the stent supported by the stent cover member is composed of a combination of a plurality of tubular body forming elements formed by bending a series of continuous filaments so that a linear portion and a bent portion are sequentially continued.
- the diameter is increased or decreased by changing the opening angle.
- the present invention it is desirable to carry a drug having an intimal growth inhibitory effect on the stent cover member and to carry a drug having a thrombus formation inhibitory effect on the stent.
- a coating agent containing a drug having an intimal proliferation inhibitory effect may be adhered to the outer peripheral surface of the stent cover member to form a drug carrying layer.
- the stent cover member and the stent device using the cover member according to the present invention have a size in which the cover member has an inner peripheral diameter that supports the stent in a reduced diameter state by a bioabsorbable polymer material having elasticity. Since it is formed in a cylindrical shape, the stent that has a self-expanding force acting on the self-expanding force that gradually expands from the reduced diameter to the shape memorized and recovers the shape is surely supported in the reduced diameter.
- the catheter is inserted into the vascular vessel while preventing the catheter from falling off or being displaced, and the stent can be accurately implanted at a desired stent implantation position. Further, since the cover member is plastically deformed when the diameter of the stent is expanded to a shape memorized size, it does not hinder the shape of the stent from returning to the shape memorized size.
- the stent device according to the present invention is made of a bioabsorbable polymer material like the stent, the stent member can be lost in the vessel together with the stent. A procedure to remove it from the body becomes unnecessary.
- the stent cover member is a bioabsorbable polymer material having a composition ratio of poly L-lactide (PLLA) and poly ⁇ -caprolactone (PCL) in a molar ratio (mol%) of 95 to 20: 5 to 80.
- PLLA poly L-lactide
- PCL poly ⁇ -caprolactone
- a bioabsorbable polymer material having a composition ratio of poly L-lactide (PLLA) and poly ⁇ -caprolactone (PCL) in a molar ratio (mol%) of 95 to 20: 5 to 80 is elastic and flexible. Therefore, it is possible to suppress deformation in the radial direction while easily deforming following a bent vessel, and making it possible to implement insertion into the vessel with good follow-up to the vessel.
- PLLA poly L-lactide
- PCL poly ⁇ -caprolactone
- the stent cover member is provided with openings at a predetermined ratio, it prevents the inner wall of the blood vessel from being completely covered when implanted in the blood vessel, and branches from the blood vessel into which the stent is implanted. It is possible to secure blood flow to the side branch.
- the stent device according to the present invention can be used to accurately implant the stent at a desired stent implantation position, the stent cover member that is implanted into the blood vessel integrally with the stent is inhibited from intimal proliferation.
- the drug is properly released to the inner wall of the blood vessel at the site where the stent is implanted, and the restenosis of the blood vessel due to intimal proliferation caused by the implantation of the stent can be suppressed.
- epigallocatechin galade with a purity of 94% or more as a drug contained in the stent cover member, the proliferation of vascular smooth muscle cells after stent implantation can be efficiently prevented, and restenosis is achieved. Can be suppressed over a long period of time.
- the drug can be released into the blood vessel and thrombus generation can be suppressed.
- FIG. 1 is a perspective view showing a stent cover member constituting a stent device according to the present invention and a stent supported by the cover member.
- FIG. 2 is a perspective view showing a stent having a diameter expanded to be implanted in a blood vessel.
- FIG. 3 is a perspective view showing a stent device in which a reduced diameter stent is supported by a stent cover member.
- FIG. 4 is a longitudinal sectional view of the stent device according to the present invention.
- FIG. 5 is a characteristic diagram showing the relationship between the elastic characteristics of the stent cover member and the expanded state of the stent.
- FIG. 6 is a cross-sectional view showing a state where the stent device is mounted on the balloon of the balloon catheter.
- FIG. 7 is a perspective view showing another example of the stent cover member constituting the stent device according to the present invention.
- FIG. 8 is a cross-sectional view showing a stent cover member carrying a drug.
- FIG. 9 is a cross-sectional view showing another example of a stent cover member carrying a drug.
- FIG. 10 is a cross-sectional view showing a state in which the balloon is expanded to expand the diameter of the stent together with the stent cover member.
- FIG. 11 is a cross-sectional view showing a state where a stent is implanted in a blood vessel.
- FIG. 12 is a perspective view showing a stent cover member showing another embodiment of the stent device according to the present invention and a stent supported by the stent cover member.
- FIG. 13 is a side view showing a state where the stent covered with the stent cover member is mounted on the balloon of the balloon catheter.
- a stent device 1 using a stent cover member according to the present invention is formed into a tubular shape using a bioabsorbable polymer material as a constituent material, and is implanted in a blood vessel of a living body, for example, a blood vessel such as a coronary artery.
- a blood vessel such as a coronary artery.
- the stent 2 When the stent 2 is inserted, the stent 2 having a shape memorized so that the blood vessel can be supported from the inside thereof, and the stent 2 covering the stent 2 from the outer peripheral side and supporting the stent in a state of being reduced in diameter from the memorized size.
- a cover member 3 3
- the stent 2 used in the present embodiment is formed by bending a series of continuous filaments 4 made of a bioabsorbable polymer so that a straight portion 5 and a bent portion 6 are sequentially continued.
- the plurality of tubular body forming elements 7 are combined and formed into a cylindrical shape so as to form one flow path from one end side to the other end side.
- the size of the stent 2 is appropriately selected according to a blood vessel such as a blood vessel of a living body to be implanted.
- the outer diameter R 1 is 2 to 5 mm and the length L 1 is the size when implanted in the blood vessel.
- the stent 2 is formed of a bioabsorbable polymer that does not adversely affect the living body when it is mounted in a blood vessel of a living body such as a human body.
- a bioabsorbable polymer an aliphatic polyester having a crosslinked structure imparting shape memory characteristics is used.
- polylactic acid polylactide: PLA
- polyglycolic acid PGA
- polyglactin polyglycol
- polydioxanone polyglyconate
- polyglycolic acid or a copolymer of polylactic acid and ⁇ -caprolactone is used.
- a bioabsorbable polymer in which two or more of these materials are combined can be used.
- poly L-lactide (PLLA) is used as the bioabsorbable polymer used here in consideration of safety to the living body and the like.
- PLLA used here has a glass transition point (Tg) of 55 ° C. to 70 ° C. and a melting point (Tm) of 170 ° C. to 185 ° C.
- a stent 2 formed by combining a plurality of tubular body forming elements 7 formed by bending a continuous linear body 4 into a zigzag shape so that a linear portion 5 and a bent portion 6 are sequentially continued is a linear
- the opening angle ( ⁇ ) of the bent portion 6 of the strip 4 is increased, the outer peripheral diameter is increased and the diameter is expanded, and when the bent portion 6 is closed, the outer peripheral diameter is decreased. It is said.
- the stent 2 formed by combining a plurality of linear bodies 4 bent in a zigzag shape has a shape memory in such a size that the bent portions 6 of the linear bodies 4 are opened and expanded in diameter as shown in FIG. Is done.
- the size of the stent 2 that is memorized in shape is large enough to be implanted in a blood vessel and support the blood vessel from the inside.
- the stent 2 that is implanted in a blood vessel of a living body and has a shape memorized in a size sufficient to support the blood vessel has a size that enables insertion into the blood vessel as shown in FIG.
- the diameter is reduced.
- This diameter reduction is performed by compressing the stent 2 formed in a tubular shape by applying pressure from the outer periphery. For example, it is performed by inserting the stent 2 having the expanded diameter into a tubular mold having an inner diameter of a size to be reduced while being compressed.
- a stent detection member 8 that enables detection by X-ray irradiation is attached to the stent 2.
- the stent detection member 8 is made of a metal having a low X-ray transmittance, higher rigidity than a bioabsorbable polymer, and excellent biocompatibility. In this embodiment, it is made of gold.
- the stent detection members 8 are attached to both ends of the stent 2 one by one as shown in FIG.
- the stent detection member 8 is attached to both ends of the stent 2 so that the implantation region of the stent 2 in the blood vessel can be easily recognized.
- the stent 2 having the diameter reduced from the shape memory size is inserted into the living body and heated by the body temperature, the self-expanding force acts, and the shape memory size is reduced from the reduced diameter state.
- the diameter gradually increases and the shape recovers. If such a shape recovery function acts in the middle of the transfer into the vasculature and expands, the position of the balloon catheter with respect to the balloon can be easily shifted by receiving frictional force such as contacting the inner wall of the blood vessel, It causes dropout.
- a stent cover member 3 for reducing the diameter of the stent 2 and supporting it by pressure-bonding on the balloon of the balloon catheter is used.
- This cover member 3 for stents is formed in the cylinder shape using the bioabsorbable polymer material which has a fixed elastic force.
- the stent cover member 3 has an inner peripheral diameter R 3 that is smaller than the outer diameter R 2 of the stent 2 that is reduced in diameter and is mounted on the balloon so that the stent 2 is reduced in diameter and supported on the balloon. It has a cylindrical shape.
- the stent cover member 3 is supported on the balloon with a constant pressure because the stent 2 having a reduced diameter is mounted on the balloon of the balloon catheter without causing positional displacement. Therefore, the stent cover member 3 is formed using a bioabsorbable polymer material having a certain elastic force.
- the stent cover member 3 is preferably formed of the same kind of bioabsorbable polymer material as the stent 2. This is to improve the adhesion of the stent cover member 3 to the stent 2 due to its excellent affinity with each other, and to reliably support the stent 2 that has been memorized in the expanded diameter state in a reduced diameter state. This is to make it possible.
- the stent cover member 3 is made of a copolymer of poly L-lactide (PLLA), which is a kind of aliphatic polyester, and poly ⁇ -caprolactone (PCL).
- PLLA poly L-lactide
- PCL poly ⁇ -caprolactone
- the copolymer of PLLA and PCL used here has a crosslinked structure and high elasticity.
- the elastic force of the copolymer of PLLA and PCL is larger than that of poly L-lactide (PLLA).
- the stent cover member 3 is placed on the outer periphery side of the stent 2 that is mounted on the balloon and reduced in size to be transferred through the blood vessel, thereby reducing the diameter of the stent 2. I support it in the state.
- the stent cover member 3 is formed of a bioabsorbable polymer material having an elastic force higher than that of the bioabsorbable polymer material mainly composed of PLLA constituting the stent 2. As shown in FIG. 4, it is pressed against the outer peripheral surface of the stent 2 made of a bioabsorbable polymer material mainly composed of PLLA, and is elastically supported so as to compress the stent 2 into a reduced diameter state.
- the stent device 1 according to the present invention is inserted into a living body vessel and heated by body temperature, the stent 2 maintains a contracted state and expands in diameter while being transferred into the blood vessel. Can be prevented from falling off or being displaced from the balloon.
- the stent cover member 3 formed into a cylindrical shape using a copolymer of PLLA and PCL, which is a bioabsorbable polymer material, has an inner diameter in the initial reduced diameter state due to the expansion force of the balloon provided on the catheter.
- it When it is expanded from the state having R 3 , it has a characteristic of reducing the elastic force as shown in FIG.
- the cover member 3 When the cover member 3 is expanded by a certain amount or more, the cover member 3 loses its elastic force and plastically deforms without returning to the initial large size. Therefore, when the stent 2 is expanded by a certain amount or more, the stent cover member 3 is in a state of being plastically deformed by reducing the elastic force.
- the stent cover member 3 When the stent 2 mounted on the balloon of the balloon catheter is expanded by a certain amount or more by the expansion force of the balloon 12, the stent cover member 3 having such characteristics will be plastically deformed without elastic recovery. When the diameter of the stent cover member 3 is expanded until it is plastically deformed, the stent 2 expands to a size memorized by a self-returning force larger than the restoring force of the cover member 3, and maintains that state. .
- the cover member 3 is formed in a size having an inner peripheral diameter that supports the stent 2 mounted on the balloon in a reduced diameter state from a material having elasticity, from the outer peripheral side.
- the stent 2 is maintained in a reduced diameter state and is supported by crimping on the balloon of the balloon catheter, so that it can be reliably transferred to a desired implantation position while preventing displacement and dropping of the balloon during insertion into the blood vessel.
- the cover member 3 is plastically deformed when the diameter is expanded by a certain amount, when the diameter is expanded by expansion of the balloon, the cover member 3 is plastically deformed and the self-recovery of the stent 2 whose shape is memorized in the expanded diameter. The diameter can be expanded without hindering the force, and the blood vessel is supported by the stent 2.
- the stent device 1 is mounted on the balloon 12 of the balloon catheter 11 while being supported in a state where the stent 2 is reduced in diameter by the stent cover member 3.
- the stent device 1 mounted on the balloon 12 is transferred to a lesion site where the stent 2 is implanted while bending with the balloon catheter 11 or passing through a meandering blood vessel.
- the stent 2 and the stent cover member 3 mounted on the balloon 12 are required to be able to follow the bent and meandering blood vessels.
- the stent cover member 3 is required to have an elastic force for supporting the stent 2 on the balloon 12 in a state in which the diameter of the stent 2 is reduced.
- the stent cover member 3 may be bent when inserted into a bent and meandering blood vessel, or both ends of the stent cover member 3 may contact the inner wall of the blood vessel, damaging the blood vessel. Furthermore, there is a possibility that the stent 2 cannot be reliably supported on the balloon 12 due to friction and resistance with the inner wall.
- the stent 2 is formed of PLLA and easily deformed, and is formed so that it can be inserted into a bent or meandering blood vessel with good followability.
- the stent 2 includes a plurality of tubular body forming elements 7 formed by bending a continuous linear body 4 so that a linear portion 5 and a bent portion 6 are sequentially continuous. And is formed in a cylindrical shape so as to form one flow path from one end side to the other end side.
- the stent cover member 3 for supporting the stent 2 in a reduced diameter state is formed so as to have an elastic modulus in the range of 2 ⁇ 10 7 to 2 ⁇ 10 9 Pascals (Pa) at 37 ° C. It can have the flexibility to elastically deform so as not to hinder the deformation of the stent 2 that is easily deformed in the axial direction.
- the stent cover member 3 having such an elastic modulus is inserted into the blood vessel together with the stent 2, the stent cover member 3 easily elastically deforms following the bent and meandering blood vessel, and contacts the blood vessel at the time of insertion to cause damage. The occurrence of such accidents can be suppressed.
- the stent cover member 3 can be securely supported on the balloon 12 by elastically supporting the stent 2 in a reduced diameter state, and can be displaced or dropped from the balloon 12 during insertion into the blood vessel. Can be prevented.
- the elastic modulus of the cover member 3 for stent is 2 ⁇ 10 7 (Pa) or less, the stent cover member 3 can be easily elastically deformed following a bent blood vessel, but the stent 2 is supported in a reduced diameter state. Sufficient elasticity cannot be obtained. Further, if the elastic modulus is 2 ⁇ 10 9 (Pa) or more, sufficient flexibility cannot be obtained, and it becomes impossible to insert with good follow-up following the shape of the blood vessel, and the blood vessel is damaged during the insertion. There is a risk of letting you.
- the stent cover member 3 is formed so that the elastic modulus is in the range of 2 ⁇ 10 7 to 2 ⁇ 10 9 at 37 ° C.
- the copolymer of PLLA and PCL constituting the stent cover member 3 can change the elastic characteristics and appropriately set elasticity and flexibility by appropriately selecting the composition ratio of PCL to PLLA. Further, by adding 5 mol% of PCL at a molar ratio (mol%) to PLLA, the bending rigidity is reduced by half, and the elasticity and flexibility are remarkably improved.
- the cover member 3 formed of only PCL is easily stretched with a small force and breaks.
- PCL is added in an amount of 80 to 90 mol% with respect to PLLA, the melting temperature is lowered to around body temperature. If the melting temperature of the stent cover member 3 is near or below the body temperature, the stent cover member 3 is softened or melted in the blood vessel and cannot sufficiently support the stent 2.
- the bioabsorbable polymer material constituting the stent cover member 3 is a copolymer of PLLA and PCL, and the composition ratio of PLLA and PCL is 95 to 20: 5 in terms of molar ratio (mol%). It is desirable to be in the range of ⁇ 80.
- the elastic modulus at 37 ° C. is in the range of 2 ⁇ 10 7 to 2 ⁇ 10 9 (Pa).
- the stent cover member 3 can be configured.
- the stent cover member 3 covering the stent 2 is implanted in contact with the inner wall of the blood vessel.
- the drug can be effectively administered to the inner wall of the blood vessel in which the stent 2 is implanted. Therefore, by containing a drug having an intimal proliferation inhibitory effect in the stent cover member 3, the administration effect of the drug can be improved, and the occurrence of intimal proliferation, which has been pointed out to be increased by the implantation of the stent, is reported Can be suppressed.
- An immunosuppressive agent or an antitumor agent is used as a drug having an intimal proliferation inhibitory effect contained in the stent cover member 3.
- epigallocatechin gallate (EGCg) having a high antioxidant activity and a function of suppressing the proliferation of vascular smooth muscle cells is used as a drug having an intimal growth inhibitory effect.
- EGCg is a kind of green tea polyphenol and is extracted from green tea. The effect of EGCg is higher as the purity is higher, so that the EGCg has a purity of 94% or more, and preferably has a purity of 98% or more.
- medical agent contained in the cover member 3 for stents is added to the bioabsorbable polymer material which comprises the cover member 3, and this bioabsorbable polymer material is contained in the stent cover member 3 by shape
- the drug is added in a range that does not affect the physical characteristics of the stent cover member 3. That is, the drug is added to the material constituting the cover member 3 such that the elastic modulus of the stent cover member 3 can be maintained in the range of 2 ⁇ 10 7 to 2 ⁇ 10 9 (Pa) at 37 ° C.
- EGCg When EGCg is used as the medicine contained in the stent cover member 3, it is added in the range of 1 to 30 parts by weight with respect to 100 parts by weight of the bioabsorbable polymer material constituting the cover member 3. In this embodiment, 1 to 30 parts by weight of EGCg is added to 100 parts by weight of a copolymer of PLLA and PCL.
- the stent cover member 3 formed by adding EGCg to the bioabsorbable polymer material in such a range could maintain the elastic modulus at 37 ° C. in the range of 2 ⁇ 10 7 to 2 ⁇ 10 9 (Pa). .
- EGCg used for suppressing the proliferation action of vascular smooth muscle cells is gradually released for about 6 months after the stent device 1 is implanted in the blood vessel.
- the stent cover member 3 In order for the stent cover member 3 to have an elastic modulus at 37 ° C. in the range of 2 ⁇ 10 7 to 2 ⁇ 10 9 (Pa), 30 parts by weight with respect to 100 parts by weight of the copolymer of PLLA and PCL. The following is desirable.
- the intimal proliferation suppressing effect is functioned for about 6 months.
- the stent cover member 3 used for supporting the stent 2 in a reduced diameter state having a size, an outer peripheral diameter R 1 of 2 to 5 mm, and a length L 1 of 10 to 40 mm, It is desirable to contain 5 to 8 ⁇ g of an immunosuppressive agent or antitumor agent capable of exhibiting a growth inhibitory effect per 1 mm length.
- the amount of the drug contained in the stent cover member 3 can be estimated from the amount of the drug carried on a conventionally used stent.
- the stent 2 also carry a drug.
- the drug can be directly administered to the lumen of the blood vessel in which the stent 2 is implanted. Therefore, the stent 2 carries a drug having a thrombus formation inhibitory effect.
- a drug having a thrombus formation inhibitory effect any one of an antiplatelet agent, an anticoagulant and a thrombolytic agent is used.
- These drugs are carried on the stent 2 by being added to the bioabsorbable polymer material constituting the stent 2. Alternatively, it is supported by depositing a solution of a bioabsorbable polymer containing a drug on the surface of the stent 2 to form a drug-containing layer.
- the stent cover member 3 is loaded with a drug capable of exhibiting an intimal proliferation inhibitory effect
- the stent 2 is loaded with a drug having a thrombus formation inhibitory effect, whereby the stent device 1 is implanted. It is possible to administer a drug capable of efficiently exhibiting an intimal growth inhibitory effect to the inner wall and administer a drug having a thrombus formation inhibitory effect to the lumen of the blood vessel, thereby improving the intimal proliferation inhibitory effect and the thrombus formation inhibitory effect.
- the blood vessel into which the stent device 1 is implanted has a portion where a plurality of side branches are branched. If the stent device 1 is implanted in such a site and the entire inner wall of the blood vessel is covered with the stent 2 or the cover member 3, blood flow to the side branch may not be ensured.
- the stent cover member 3 according to the present invention is provided with a plurality of openings 9 as shown in FIGS. 1 and 3 to ensure blood flow from the main blood vessel to the side branch.
- the opening 9 provided in the cover member 3 is formed with an opening ratio of 10 to 70% with respect to the surface area of the inner wall of the blood vessel covered by the stent 2.
- the opening ratio of the opening 9 of the stent cover member 3 is 10% or less, it is difficult to ensure blood flow to the side branch existing in the region where the stent 2 is implanted. Therefore, in order to ensure blood flow from the main blood vessel to the side branch, an aperture ratio of 10% or more is necessary. Further, if the aperture ratio exceeds 70%, sufficient mechanical strength as the cover member 3 cannot be obtained, and the stent 2 that has been memorized in the expanded diameter state cannot be supported in the reduced diameter state. .
- the shape of the opening 9 formed in the stent cover member 3 is not limited to a circle but may be any shape such as a triangle and a rectangle. As shown in FIG. You may make it form by dispersion
- the stent 2 used here is formed of a plurality of tubular bodies formed by bending a series of continuous filaments 4 so that a straight portion 5 and a bent portion 6 are successively continued. Supplying blood to the cover member 3 side is realized by using a combination of the elements 7 and having a sufficient opening rate guaranteed. Therefore, in the present invention, it is desirable to use the stent 2 configured by combining the striatum and having a large aperture ratio.
- the stent cover member 3 is required to have a certain elastic force in order to reliably support the stent 2 whose shape has been memorized in the expanded diameter state in the reduced diameter state. Therefore, as described above, the amount of the medicine contained in the stent cover member 3 is limited.
- a medicine carrying layer 13 may be provided on the surface of the stent cover member 3 as shown in FIG.
- This drug-carrying layer 13 has an anti-platelet, anti-coagulant, or thrombolytic agent that has a thrombus formation inhibitory effect in a solution of PLLA and PCL copolymer in dioxane, and an intimal growth inhibitory effect. It is formed by applying a coating agent in which an immunosuppressive agent or an antitumor agent is dissolved and applied to the surface of the stent cover member 3.
- a drug-containing solution in which an EGCg-containing antithrombotic agent in which EGCg is mixed in an antithrombotic agent is dissolved in a solution in which a copolymer of PLLA and PCL is dissolved in dioxane is prepared, and a stent cover is prepared in this solution.
- the member 3 is immersed. By removing the stent cover member 3 from the drug solution, as shown in FIG. 9, the drug-carrying layers 13 and 14 are formed on the inner and outer peripheral surfaces of the stent 2 in contact with the outer peripheral surface.
- the stent cover member 3 used at this time has an inner peripheral diameter of 1 to 3 mm when the diameter is reduced and an inner diameter so that the stent 2 having a length of 10 to 40 mm is supported in a reduced diameter state.
- One having a length of 1 to 3 mm and a length of 10 to 42 mm was used.
- the drug carrying layer when forming the drug carrying layer on the stent cover member 3 and immersing it in the drug-containing solution, it may be performed by immersing it in the drug-containing solution while supporting the stent 2.
- the drug carrying layer is formed on the outer peripheral surface and the inner peripheral surface of the stent cover member 3 as well as on the lumen of the stent 2. Further, the drug-containing solution enters the surface of the stent 2 to form a drug carrying layer.
- the stent device 1 configured as described above into a lesion site in a blood vessel.
- it is mounted on the balloon 12 of the balloon catheter 11 together with the stent cover member 3 as shown in FIG.
- the balloon 12 is in a deflated state.
- the stent device 1 mounted on the balloon 12 is bent together with the balloon catheter 11 or passes through a meandering blood vessel, and is transferred to a lesioned portion which is an implantation position.
- the stent device 1 transferred to the lesioned part is expanded in diameter by supplying an expansion medium to the balloon 12 and expanding as shown in FIG.
- the stent cover member 3 When the diameter of the stent 2 is expanded to the size memorized by the balloon 12 or to the vicinity of the size, the stent cover member 3 loses its elastic force and plastically deforms. When the return force of the stent 2 to the shape memory state becomes superior to the elastic force of the stent cover member 3, the stent 2 returns to the shape memory expanded diameter and is self-expanding. The inner wall of the blood vessel 15 is expanded and supported. Thereafter, the expansion medium supplied to the balloon 12 is sucked, the balloon 12 is deflated, and the balloon catheter 11 is pulled out from the blood vessel 15 as shown in FIG.
- the stent cover member 3 is integrated with the expanded stent 2 and is held in close contact with the inner wall of the blood vessel by the stent 2 that returns to its expanded shape with a shape memory.
- the drug can be efficiently administered to the inner wall of the blood vessel.
- the stent cover member 3 formed of a copolymer of PLLA and PCL has a higher decomposition rate than the stent 2 formed of PLLA, so that the stent 2 has a function of expanding and supporting the blood vessel. Slow release of the drug can be achieved during the period during which it is exerted.
- a stent whose shape is memorized in an expanded size can be implanted at a desired implantation position without causing displacement or dropping of the balloon catheter with respect to the balloon during insertion into the blood vessel.
- the intima can be transferred and implanted until the intima is gradually released at this implantation position, while allowing the blood vessel to be accurately expanded and supporting the blood vessel, while slowly releasing a drug having an intimal growth inhibitory effect and a thrombus formation inhibitory effect.
- a stent device that suppresses proliferation and thrombus formation can be provided.
- the present invention is based on a bioabsorbable polymer material.
- the shape of the stent that is formed and memorized in a size that expands beyond the inner diameter of the vessel when implanted in the vessel, and is restored to its expanded shape by being heated by body temperature. Therefore, it is not necessary to carry a drug on the stent cover member 3 as long as it is only to achieve mounting and support on the balloon of the catheter and to achieve accurate implantation at a desired stent implantation position.
- the stent cover member 3 may be formed of only a bioabsorbable polymer material that has a certain elastic force and plastically deforms when expanded over a certain amount.
- the stent cover member 3 is opened as shown in FIG. It may be formed in a cylindrical shape having a smooth outer peripheral surface with no part or the like.
- the copolymer of PLLA and PCL constituting the above-described stent cover member 3 has a heat shrink property. Therefore, the cover member 3 may be covered on the outer peripheral side of the stent 2 using this heat shrinkage characteristic.
- the stent cover member 3 is formed in a cylindrical shape having an inner peripheral diameter R 4 slightly larger than the outer peripheral diameter R 2 of the reduced diameter stent 2 mounted on the balloon of the balloon catheter.
- the cover member 3 is placed on the stent 2 having a reduced diameter.
- the stent 2 covered with the cover member 3 is mounted on the balloon 12 of the balloon catheter 11.
- the cover member 3 covering the stent 2 mounted on the balloon 12 is subjected to heat treatment, and the cover member 3 is thermally contracted to a size having an inner peripheral diameter R 3 smaller than the outer peripheral diameter R 2 of the stent 2.
- the stent cover member 3 can be heat-shrinked into a cylindrical shape having an inner peripheral diameter R 3 smaller than the outer peripheral diameter R 2 of the stent 2, so that the reduced diameter stent 2 can be supported by pressure on the balloon 12. .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
Abstract
Description
Claims (14)
- 形状記憶特性を有する生体吸収性ポリマー材料により筒状に形成されてなり、脈管内に植え込まれたときに上記脈管を内部から支持可能とする大きさに形状記憶されたステントを外周側から覆って、上記ステントを上記形状記憶された大きさより縮径された状態に支持するステント用カバー部材であって、
上記ステント用カバー部材は、弾性力を有する生体吸収性ポリマー材料により筒状に形成され、バルーンカテーテルのバルーン上に縮径された状態で装着される上記ステントを上記縮径された状態に支持する内周径を有する大きさに形成されてなり、上記ステントが上記形状記憶された大きさに拡径されるとき、塑性変形して上記ステントの支持を解放することを特徴とするステント用カバー部材。 - 上記ステント用カバー部材を構成する生体吸収性ポリマー材料は、ポリL-ラクチド(PLLA)とポリε-カプロラクトン(PCL)との共重合体(LCL)であって、上記PLLAと上記PCLの組成比がモル比(mol%)で95~20:5~80の範囲にあることを特徴とする請求項1記載のステント用カバー部材。
- 上記ステント用カバー部材は、37℃における弾性率が2×107~2×109パスカル(Pa)の範囲にあることを特徴とする請求項1記載のステント用カバー部材。
- 上記ステント用カバー部材は、表面積に対し10~70%の開口率で複数の開口部が形成されていることを特徴とする請求項1~3のいずれか1に記載のステント用カバー部材。
- 上記ステント用カバー部材には、内膜増殖抑制効果を有する薬剤が含有されていることを特徴とする請求項1~4のいずれか1に記載のステント用カバー部材。
- 上記ステント用カバー部材を構成する生体吸収性ポリマー材料100重量部に対し、純度を94%以上とするエピガロカテキンガレード(EGCg)が1~30重量部添加されていることを特徴とする請求項1~4のいずれか1に記載のステント用カバー部材。
- 形状記憶特性を有する生体吸収性ポリマー材料により管状に形成され、脈管内に植え込まれたときに上記脈管を内部から支持可能とする大きさに形状記憶されたステントと、
上記形状記憶された大きさより縮径した状態でバルーンカテーテルのバルーン上に装着され、上記バルーンの膨張によって拡張されるステントをその外周側から覆って上記縮径した状態に支持するステント用カバー部材とからなり、
上記ステント用カバー部材は、弾性力を有する生体吸収性ポリマー材料により筒状に形成され、上記ステントを上記縮径された状態に支持する内周径を有する大きさに形成されてなり、上記ステントが上記形状記憶された大きさに拡径されるとき、塑性変形して上記ステントの支持を解放することを特徴とするステント装置。 - 上記ステント用カバー部材は、37℃における弾性率が2×107~2×109パスカル(Pa)の範囲にあることを特徴とする請求項7記載のステント装置。
- 上記ステント用カバー部材を構成する生体吸収性ポリマー材料は、ポリL-ラクチド(PLLA)とポリε-カプロラクトン(PCL)との共重合体(LCL)であって、上記PLLAと上記PCLの組成比がモル比(mol%)で95~20:5~80の範囲にあることを特徴とする請求項7記載のステント装置。
- 上記ステントは、一連に連続する線条体を直線部分と折り曲げ部とが順次連続するように折り曲げて形成された複数の管状体形成エレメントを組み合わせて構成され、上記折り曲げ部の開き角を変化させることによって拡径、縮径されることを特徴とする請求項7~9のいずれか1に記載のステント装置。
- 上記ステント用カバー部材には、脈管内に植え込まれ拡張されたステントによって支持される脈管内壁の表面積に対し10~70%の開口率で複数の開口部が形成されていることを特徴とする請求項7~10のいずれか1に記載のステント装置。
- 上記ステント用カバー部材には、内膜増殖抑制効果を有する薬剤が担持され、上記ステントには、血栓形成抑制効果を有する薬剤が担持されていることを特徴とする請求項7~11のいずれか1に記載のステント装置。
- 上記ステント用カバー部材を構成する生体吸収性ポリマー材料100重量部に対し、純度を94%以上とするエピガロカテキンガレード(EGCg)が1~30重量部添加されていることを特徴とする請求項7~11のいずれか1に記載のステント装置。
- 上記ステント用カバー部材の外周面に、内膜増殖抑制効果を有する薬剤を含有したコーティング剤が被着されて薬剤担持層が形成されていることを特徴とする請求項7~13のいずれか1に記載のステント装置。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11809445.7A EP2596766A4 (en) | 2010-07-20 | 2011-07-19 | STENT COVER MEMBER AND STENT DEVICE |
CA2804261A CA2804261A1 (en) | 2010-07-20 | 2011-07-19 | Stent covering member and stent apparatus |
US13/811,190 US9668897B2 (en) | 2010-07-20 | 2011-07-19 | Stent cover member and stent apparatus |
AU2011280836A AU2011280836A1 (en) | 2010-07-20 | 2011-07-19 | Stent cover member and stent device |
KR1020127034351A KR20130096645A (ko) | 2010-07-20 | 2011-07-19 | 스텐트용 커버 부재 및 스텐트 장치 |
JP2012525324A JP5698237B2 (ja) | 2010-07-20 | 2011-07-19 | ステント用カバー部材及びステント装置 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-163377 | 2010-07-20 | ||
JP2010163377 | 2010-07-20 | ||
JP2011-083374 | 2011-04-05 | ||
JP2011083374 | 2011-04-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012011269A1 true WO2012011269A1 (ja) | 2012-01-26 |
Family
ID=45496702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/004080 WO2012011269A1 (ja) | 2010-07-20 | 2011-07-19 | ステント用カバー部材及びステント装置 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9668897B2 (ja) |
EP (1) | EP2596766A4 (ja) |
JP (1) | JP5698237B2 (ja) |
KR (1) | KR20130096645A (ja) |
AU (1) | AU2011280836A1 (ja) |
CA (1) | CA2804261A1 (ja) |
WO (1) | WO2012011269A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014188437A2 (en) | 2013-05-23 | 2014-11-27 | S.T.S. Medical Ltd. | Shape change structure |
JP2015525104A (ja) * | 2012-06-15 | 2015-09-03 | アボット カルディオバスキュラー システムズ インコーポレーテッドAbbott Cardiovascular Systems Inc. | ポリ(l−ラクチド)と親水性ポリマーとのブロックコポリマーでできている生体吸収性ポリマーに関連したスキャフォールド |
JP2015527920A (ja) * | 2012-07-23 | 2015-09-24 | アボット カーディオバスキュラー システムズ インコーポレイテッド | 形状記憶生体再吸収性ポリマーの末梢スキャフォールド |
WO2015190541A1 (ja) * | 2014-06-12 | 2015-12-17 | 国立研究開発法人国立循環器病研究センター | ステント |
CN109568661A (zh) * | 2018-12-27 | 2019-04-05 | 郑州大学 | 一种高韧性组织工程血管支架及其制备方法 |
JP2019528119A (ja) * | 2016-08-24 | 2019-10-10 | エム. アイ. テック カンパニー リミテッド | 薬物放出型生分解性ステント |
US10912663B2 (en) | 2014-11-26 | 2021-02-09 | S.T.S. Medical Ltd. | Shape change structure for treatment of nasal conditions including sinusitis |
WO2023127943A1 (ja) * | 2021-12-28 | 2023-07-06 | 日本ゼオン株式会社 | 消化器系ステント |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015157281A1 (en) | 2014-04-08 | 2015-10-15 | Boston Scientific Scimed, Inc. | Partially coated stents |
US20150374485A1 (en) * | 2014-06-27 | 2015-12-31 | Cordis Corporation | Targeted perforations in endovascular device |
EP3381415B1 (en) * | 2015-11-26 | 2021-06-23 | JAPAN Medical Device Technology Co., Ltd. | Bioabsorbable stent |
EP3551140A4 (en) | 2016-12-09 | 2020-07-08 | Zenflow, Inc. | SYSTEMS, DEVICES AND METHODS FOR THE PRECISE RELEASE OF AN IMPLANT IN THE PROSTATIC urethra |
KR101964635B1 (ko) * | 2017-07-25 | 2019-04-02 | 주식회사 엠아이텍 | 이탈 방지용 스텐트 및 그 제조방법 |
KR102355542B1 (ko) * | 2018-10-02 | 2022-01-26 | 주식회사 티엠디랩 | 형상기억 고분자를 포함하는 혈관 문합용 부재 |
JP2023502997A (ja) | 2019-11-19 | 2023-01-26 | ゼンフロー, インコーポレイテッド | 前立腺部尿道内のインプラントの正確な展開および撮像のためのシステム、デバイス、および方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992015342A1 (en) | 1991-03-08 | 1992-09-17 | Keiji Igaki | Stent for vessel, structure of holding said stent, and device for mounting said stent |
WO2000013737A1 (fr) | 1998-09-08 | 2000-03-16 | Kabushikikaisha Igaki Iryo Sekkei | Stent pour vaisseaux |
WO2004103450A1 (ja) | 2003-05-23 | 2004-12-02 | Kabushikikaisha Igaki Iryo Sekkei | ステント供給装置 |
JP2005534425A (ja) * | 2002-08-05 | 2005-11-17 | ボストン サイエンティフィック リミテッド | 保持材を有する分離可能な医療装置 |
JP2008253707A (ja) | 2007-04-05 | 2008-10-23 | Bio Verde:Kk | 薬剤溶出ステント |
WO2009157164A1 (ja) | 2008-06-27 | 2009-12-30 | 株式会社 京都医療設計 | 脈管用ステント |
JP2010521211A (ja) * | 2007-03-15 | 2010-06-24 | メディノール リミテッド | カバードステントバルーン及びその使用方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5980564A (en) * | 1997-08-01 | 1999-11-09 | Schneider (Usa) Inc. | Bioabsorbable implantable endoprosthesis with reservoir |
US20050033399A1 (en) | 1998-12-03 | 2005-02-10 | Jacob Richter | Hybrid stent |
US20030050692A1 (en) * | 2000-12-22 | 2003-03-13 | Avantec Vascular Corporation | Delivery of therapeutic capable agents |
NO316189B1 (no) | 2002-01-16 | 2003-12-22 | Norsk Hydro As | Kontrollanordning for stigeror |
US20030153971A1 (en) | 2002-02-14 | 2003-08-14 | Chandru Chandrasekaran | Metal reinforced biodegradable intraluminal stents |
US20030153972A1 (en) * | 2002-02-14 | 2003-08-14 | Michael Helmus | Biodegradable implantable or insertable medical devices with controlled change of physical properties leading to biomechanical compatibility |
US8968390B2 (en) * | 2004-09-27 | 2015-03-03 | Medinol Ltd. | Covering for an endoprosthetic device and methods of using for aneurysm treatment |
DE102005056532A1 (de) * | 2005-11-28 | 2007-05-31 | Mnemoscience Gmbh | Entfernung von tubulären Gewebestützen |
CA2563130A1 (en) * | 2006-10-11 | 2008-04-11 | Andrew Hoffmann | Drug eluting stent for prevention of late in-stent thrombosis |
EP2117463B1 (en) | 2007-03-07 | 2018-11-14 | Boston Scientific Limited | Radiopaque polymeric stent |
-
2011
- 2011-07-19 WO PCT/JP2011/004080 patent/WO2012011269A1/ja active Application Filing
- 2011-07-19 KR KR1020127034351A patent/KR20130096645A/ko not_active Application Discontinuation
- 2011-07-19 JP JP2012525324A patent/JP5698237B2/ja not_active Expired - Fee Related
- 2011-07-19 US US13/811,190 patent/US9668897B2/en not_active Expired - Fee Related
- 2011-07-19 AU AU2011280836A patent/AU2011280836A1/en not_active Abandoned
- 2011-07-19 CA CA2804261A patent/CA2804261A1/en not_active Abandoned
- 2011-07-19 EP EP11809445.7A patent/EP2596766A4/en not_active Withdrawn
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992015342A1 (en) | 1991-03-08 | 1992-09-17 | Keiji Igaki | Stent for vessel, structure of holding said stent, and device for mounting said stent |
WO2000013737A1 (fr) | 1998-09-08 | 2000-03-16 | Kabushikikaisha Igaki Iryo Sekkei | Stent pour vaisseaux |
JP2005534425A (ja) * | 2002-08-05 | 2005-11-17 | ボストン サイエンティフィック リミテッド | 保持材を有する分離可能な医療装置 |
WO2004103450A1 (ja) | 2003-05-23 | 2004-12-02 | Kabushikikaisha Igaki Iryo Sekkei | ステント供給装置 |
JP2010521211A (ja) * | 2007-03-15 | 2010-06-24 | メディノール リミテッド | カバードステントバルーン及びその使用方法 |
JP2008253707A (ja) | 2007-04-05 | 2008-10-23 | Bio Verde:Kk | 薬剤溶出ステント |
WO2009157164A1 (ja) | 2008-06-27 | 2009-12-30 | 株式会社 京都医療設計 | 脈管用ステント |
Non-Patent Citations (1)
Title |
---|
See also references of EP2596766A4 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015525104A (ja) * | 2012-06-15 | 2015-09-03 | アボット カルディオバスキュラー システムズ インコーポレーテッドAbbott Cardiovascular Systems Inc. | ポリ(l−ラクチド)と親水性ポリマーとのブロックコポリマーでできている生体吸収性ポリマーに関連したスキャフォールド |
JP2015527920A (ja) * | 2012-07-23 | 2015-09-24 | アボット カーディオバスキュラー システムズ インコーポレイテッド | 形状記憶生体再吸収性ポリマーの末梢スキャフォールド |
US10500076B2 (en) | 2012-07-23 | 2019-12-10 | Abbott Cardiovascular Systems Inc. | Shape memory bioresorbable polymer peripheral scaffolds |
US11337835B2 (en) | 2012-07-23 | 2022-05-24 | Abbott Cardiovascular Systems Inc. | Shape memory bioresorbable polymer peripheral scaffolds |
WO2014188437A2 (en) | 2013-05-23 | 2014-11-27 | S.T.S. Medical Ltd. | Shape change structure |
US10953141B2 (en) | 2013-05-23 | 2021-03-23 | S.T.S. Medical Ltd. | Shape change structure |
WO2015190541A1 (ja) * | 2014-06-12 | 2015-12-17 | 国立研究開発法人国立循環器病研究センター | ステント |
US10912663B2 (en) | 2014-11-26 | 2021-02-09 | S.T.S. Medical Ltd. | Shape change structure for treatment of nasal conditions including sinusitis |
JP2019528119A (ja) * | 2016-08-24 | 2019-10-10 | エム. アイ. テック カンパニー リミテッド | 薬物放出型生分解性ステント |
US10932928B2 (en) | 2016-08-24 | 2021-03-02 | M.I.Tech Co., Ltd. | Drug-releasing biodegradable stent |
CN109568661A (zh) * | 2018-12-27 | 2019-04-05 | 郑州大学 | 一种高韧性组织工程血管支架及其制备方法 |
WO2023127943A1 (ja) * | 2021-12-28 | 2023-07-06 | 日本ゼオン株式会社 | 消化器系ステント |
Also Published As
Publication number | Publication date |
---|---|
CA2804261A1 (en) | 2012-01-26 |
KR20130096645A (ko) | 2013-08-30 |
US9668897B2 (en) | 2017-06-06 |
AU2011280836A1 (en) | 2013-01-24 |
JP5698237B2 (ja) | 2015-04-08 |
JPWO2012011269A1 (ja) | 2013-09-09 |
EP2596766A1 (en) | 2013-05-29 |
EP2596766A4 (en) | 2014-01-08 |
US20130131778A1 (en) | 2013-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5698237B2 (ja) | ステント用カバー部材及びステント装置 | |
JP5978131B2 (ja) | ステント装置 | |
EP1981578B1 (en) | Biodegradable device | |
EP1076534B1 (en) | Stent with smooth ends | |
US6350277B1 (en) | Stents with temporary retaining bands | |
US8100963B2 (en) | Biodegradable device | |
EP1492580B1 (en) | Biodegradable stents with controlled change of physical properties leading to biomechanical compatibility | |
US20100016940A1 (en) | Biodegradable self-expanding prosthesis | |
WO2009089382A1 (en) | Biodegradable self-expanding drug-eluting prosthesis | |
JP2011502705A (ja) | 薬剤送達のためのらせん状チャンネルを有するステント | |
EP1119379A1 (en) | Drug delivery device for stent | |
EP2911710B1 (en) | Fully absorbable intraluminal devices and methods of manufacturing the same | |
US9526812B2 (en) | Biodegradable medical devices and method to control degradation of the biodegradable medical devices | |
US20220008231A1 (en) | Stent having a tacky silicone coating to prevent stent migration | |
JP6667758B2 (ja) | 生体吸収性ステント | |
JP6602293B2 (ja) | コネクタの混合構成を備えた血管ステント | |
JP5102200B2 (ja) | 生体内留置物 | |
US20140144001A1 (en) | Stent having function elements | |
US20140296968A1 (en) | Implantable vascular stent | |
JP2005118123A (ja) | ステントおよびその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11809445 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012525324 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 20127034351 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2804261 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011809445 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13811190 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2011280836 Country of ref document: AU Date of ref document: 20110719 Kind code of ref document: A |